Mitonafide

Mitonafide

SCHEMBL62046

CN(C)CCN1C(=O)c2cccc3cc([N+](=O)[O-])cc(c23)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 4/20 1.00
PABPC1 P11940 3/20 1.00
HEXA P06865 1/20 0.67
HEXB P07686 1/20 0.67
POLB P06746 5/20 0.67
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
RAD52 P43351 2/20 0.67
KDM4E B2RXH2 1/20 0.67
MAPT P10636 1/20 0.67
S1PR1 P21453 1/20 0.67
HTT P42858 1/20 0.67
RECQL P46063 1/20 0.67
RAB9A P51151 1/20 0.67
PAX8 Q06710 1/20 0.67
CYP2D6 P10635 1/20 0.67
LCK P06239 1/20 0.66
CA12 O43570 3/20 0.61
CA1 P00915 3/20 0.61
CA2 P00918 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitonafide SCHEMBL29352711 1.00 FTO (1.00) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL29499462 1.00 FTO (1.00) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL5166813 0.99 FTO (0.98) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL5781995 0.94 FTO (0.88) FTOPABPC1HEXAHEXBPOLB
SCHEMBL11441990 0.93 PABPC1 (0.87) FTOPABPC1HEXAHEXBPOLB
SCHEMBL9504075 0.93 FTO (0.87) FTOPABPC1HEXAHEXBPOLB
SCHEMBL2989147 0.92 FTO (0.85) FTOPABPC1HEXAHEXBPOLB
SCHEMBL7712243 0.90 FTO (0.81) FTOPABPC1HEXAHEXBPOLB
SCHEMBL9501524 0.89 FTO (0.80) FTOPABPC1HEXAHEXBPOLB
SCHEMBL11550721 0.88 FTO (0.79) FTOPABPC1HEXAHEXBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 8790 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-20230241057-A1 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI UNIVERSITE PARIS 13 PARIS-NORD (FR) 2023-08-03 US claimed
EP-4157282-A1 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2023-04-05 EP claimed
US-11345956-B2 Methods and compositions related to prostate cancer therapeutics THE JOHNS HOPKINS UNIVERSITY (US) 2022-05-31 US claimed
US-11207289-B2 Use of benzofuran lignans to induce IL-25 expression and suppress mammary tumor metastasis ACADEMIA SINICA (TW) 2021-12-28 US claimed
WO-2021239905-A1 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-12-02 WO claimed
US-10953073-B2 XTEN conjugate compositions and methods of making same AMUNIX PHARMACEUTICALS, INC. (US) 2021-03-23 US claimed
US-20210060040-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2021-03-04 US claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed
EP-1085891-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE Advanced Medicine, Inc. (US) 2001-03-28 EP claimed
WO-1999064054-A9 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE INC (US) 2000-03-02 WO claimed
WO-1999064054-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE, INC. (US) 1999-12-16 WO claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
EP-0502936-B1 MITONAPHIDE INFUSION SOLUTION KNOLL AG (DE) 1993-07-28 EP claimed
EP-0502936-A1 MITONAPHIDE INFUSION SOLUTION. KNOLL AG (DE) 1992-09-16 EP claimed
US-5057304-A Anticarcinogenic agents BASF AKTIENGESELLSCHAFT (DE) 1991-10-15 US claimed
WO-1991007965-A1 MITONAPHIDE INFUSION SOLUTION KNOLL AKTIENGESELLSCHAFT (DE) 1991-06-13 WO claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed